Anzeige
Mehr »
Login
Mittwoch, 23.10.2024 Börsentäglich über 12.000 News von 675 internationalen Medien
KI-Energiekrise: Wie dieser Small Cap die nukleare Zukunft des Silicon Valley befeuern könnte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
306 Leser
Artikel bewerten:
(1)

COVID-19 and chronic illnesses: Will chronic patients be collateral victims of the pandemic?

Carenity, a digital health start-up specializing in medical studies, used their platform to help measure the real-time impact of the COVID-19 pandemic on nearly 400,000 chronic patients, including impact on access to healthcare and quality of life. Carenity collaborated with Alira Health to analyze the data.

PARIS and FRAMINGHAM, Massachusetts, April 16, 2020 /PRNewswire/ -- Chronic patients represent a particularly vulnerable population in the context of this pandemic. Global estimates reveal that one person in four suffers from at least one chronic disease. The survey respondents are chronic patients with an average age of 52 years. 87% of respondents are on background treatment and living in one of the following countries: U.S., France, UK, Germany, Spain or Italy.

Michael Chekroun, founder of Carenity, commented on the results of the survey: "In this context of an unprecedented health crisis, it is important that chronic patients continue to have the best possible access to care. This is no longer the case for many, and we face a risk of therapeutic disruption. Delays in care could have serious consequences."

Using Carenity's proprietary platform, 4,717 survey responses were gathered and analyzed between March 17, 2020 and April 5, 2020, and revealed:

  • 24% of chronic patients have difficulty finding an available doctor
  • 9% have stopped and/or interrupted their background treatment
  • 10% have difficulty finding their prescription drugs in pharmacies
  • 42% have had a consultation or surgery cancelled or rescheduled

Dr. Giacomo Basadonna, Alira Health's Chief Medical Officer commented, "An important factor to consider is that this pandemic has hindered physical visits. Currently, almost all dentists have suspended patient appointments, and many physicians see their patients via internet video or by phone. Doctors are still available, and it allows us to avoid patients congregating in waiting rooms where they could be exposed to the virus. It is also likely that some patients have decided to postpone their regularly scheduled visits with their doctors for safety reasons."

Since the beginning of the confinement, 40% of patients report consulting their doctor less than usual. In addition, 3.5% of patients have stopped their treatment altogether and 5.5% have temporarily stopped taking their medication. 10% of patients say they have difficulty finding their prescription in a pharmacy.

These figures show that there is a risk of therapeutic discontinuation for patients requiring regular care and treatment.

Sophie Crozier, Head of the Stroke Unit at the Pitié-Salpêtrière Hospital in Paris noted: "We've set up a working group with other hospitals to analyze what's going on because we're seeing far fewer stroke victims, at least 50% fewer. And in cardio, it's the same: half as many heart attacks. That's not normal, and it is worrisome. Are patients afraid to get in the way? For some, they arrive too late or they die at home."

The results of this survey come at a time when general practitioners globally are raising their voices to warn of the risk of loss of opportunity for patients suffering from chronic illnesses, particularly following announcements in several countries asking citizens to reserve their medical travel for urgent care.

About Carenity:
Founded in 2011, Carenity is a social platform that brings together more than 400,000 patients and caregivers around the world to share experiences with other patients and access high quality, well-substantiated medical information.

Carenity conducts patient-focused studies whose results enable healthcare stakeholders to better and quickly understand patients' needs and improve healthcare products and services.

More information on: www.carenity.com

About Alira Health:
Alira Health is an international advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their product and business lifecycles to transform patient care. We specialize in New Product Development, Regulatory, Clinical, Global Market Access, Strategy Consulting, and Transactional Advisory services.

More information on: www.alirahealth.com

Logo - https://mma.prnewswire.com/media/452843/Alira_Health_Logo.jpg

Photo - https://mma.prnewswire.com/media/1155296/Carenity_Logo.jpg

© 2020 PR Newswire
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.